The variants below are all in the TNFRSF10A database. All fields are shown, including patient and pathogenicity information. A '+' in the DNA change field indicates that more variants were found in this patient. Variants reported in a gene database other than TNFRSF10A, are reported as the gene symbol with the number of reported variants between parenthesis.Selecting and clicking a specific line will open a detailed view showing all details per patient.At the bottom of this page a legend is provided with a short explanation of what each field contains.For a more detailed description of each field, please see the TNFRSF10A full legend here.

111 patients with lung cancer were sequenced for four different TRAIL-R1 variations. Polymorphism c.1322G>A was then sequenced for in a further 250 lung cancer patients. This polymorphism could be a modifier in patient risk to lung cancer.

111 patients with lung cancer were sequenced for four different TRAIL-R1 variations. Polymorphism c.1322G>A was then sequenced for in a further 250 lung cancer patients. This polymorphism could be a modifier in patient risk to lung cancer.

557 female carriers of BRCA1 and 283 female carrier
of BRCA2 mutations were sequenced for the presence of two TRAIL-R1 variants. Variant 683A>C appears to be associated with an increased risk of ovarian cancer. The two variants were found in the following frequencies: 622C>G:CC=266/CG=407/GG=167 683A>C:AA=522/AC=270/CC=48

659 colorectal cancer patients were sequenced for these two variants. Variant 683G>C did not appear to be associated with an increased colorectal cancer risk. The 683C-626C haplotype conferred a 2.4 fold colorectal cancer risk.

Individually, variations 626C>G and 683A>C do not appear to be associated with an increase in breast cancer risk. However, the rare haplotype 626C-683C does appear to contribute to an increased risk to breast cancer.

111 patients with lung cancer were sequenced for four different TRAIL-R1 variations. Polymorphism c.1322G>A was then sequenced for in a further 250 lung cancer patients. This polymorphism could be a modifier in patient risk to lung cancer.

557 female carriers of BRCA1 and 283 female carrier
of BRCA2 mutations were sequenced for the presence of two TRAIL-R1 variants. Variant 683A>C appears to be associated with an increased risk of ovarian cancer. The two variants were found in the following frequencies: 622C>G:CC=266/CG=407/GG=167 683A>C:AA=522/AC=270/CC=48

659 colorectal cancer patients were sequenced for these two variants. Variant 683G>C did not appear to be associated with an increased colorectal cancer risk. The 683C-626C haplotype conferred a 2.4 fold colorectal cancer risk.

Individually, variations 626C>G and 683A>C do not appear to be associated with an increase in breast cancer risk. However, the rare haplotype 626C-683C does appear to contribute to an increased risk to breast cancer.

101 chronic lymphocytic leukemia, 32 mantle cell lymphoma, 43 prostate cancer, 40 head and neck squamous cell carcinoma and 179 bladder cancer samples were investigated for the presence of this variant. It appears that this variant is involved in the pathomechanism of a subset of these cancer types.

This variant appears to contribute to an increased resistance to TRAIL binding. All ovarian cancer cell samples tested in this instance were heterozygous for this variant. This variant was also found in 2 normal samples (20%), again heterozygous.

111 patients with lung cancer were sequenced for four different TRAIL-R1 variations. Polymorphism c.1322G>A was then sequenced for in a further 250 lung cancer patients. This polymorphism could be a modifier in patient risk to lung cancer.

In this study variants in TRAIL and the four TRAIL receptor genes were investigated for in 115 tumour samples and 40 controls. Decreased mRNA expressionof these genes in breast cancer cells appear to be due to another mechanism of gene expression than the variants listed.